| Autor: |
Fung, Kim Y.C., Priebe, Ilka, Purins, Leanne, Tabor, Bruce, Brierley, Gemma V., Lockett, Trevor, Nice, Edouard, Gibbs, Peter, Tie, Jeannie, McMurrick, Paul, Moore, James, Ruszkiewicz, Andrew, Burgess, Antony, Cosgrove, Leah J. |
| Předmět: |
|
| Zdroj: |
Cancer Biomarkers; 2013, Vol. 13 Issue 2, p75-79, 5p, 2 Charts, 1 Graph |
| Abstrakt: |
BACKGROUND: Lipocalin 2 has been implicated in colorectal tumorigenesis but its usefulness as a diagnostic marker for the disease has previously never been determined. METHODS: We have used ELISA immunoassay to measure the level of serum lipocalin 2 in a cohort consisting of colorectal cancer patients (n=196) and age/gender matched controls (n=99). RESULTS: The median concentration of lipocalin 2 was found to be significantly higher (p< 0.0001) in the patient group (105.9 ng/mL, range 10.8-444.7 ng/mL) when compared to the control subjects (86.4 ng/mL, range 17.1-190.0 ng/mL). Additionally, no significant difference was observed between disease stage (Dukes' or T stage) in the patient cohort. Receiver operating characteristic analysis was performed to determine its performance as a diagnostic marker. The area under the curve was found to be 0.641 (95% confidence interval 0.576-0.706). Furthermore, the sensitivity of lipocalin 2 was found to be 24% at 90% specificity. CONCLUSIONS: Our study indicates that lipocalin 2 is not a suitable serum biomarker for the diagnosis of CRC. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
